

Press release Leuven / 1 July 2015

Schedule for publication on 1 July 2015: press release available at www.questforgrowth.com



QUEST FOR GROWTH

Privak, fixed capital investment company established under Belgian Law

Leuven, 1 July 2015

Kiadis Pharma, a Quest for Growth portfolio company, floats successfully

Kiadis Pharma has raised € 32.7 million with its IPO on Euronext Amsterdam and Euronext Brussels at an introduction price of € 12.50 per share. The share will be listed at these exchanges from 2 July. Quest for Growth first invested in Kiadis Pharma in 2007 and, since then, has participated in a number of follow-on investment rounds. Kiadis was one of the largest unlisted holdings in the Quest for Growth portfolio.

The existing shareholders have agreed not to sell any shares within 12 months following the IPO (six months' "hard lock-up" + six months' "soft lock-up"). After the first quotation, Quest for Growth will record these shares in its books with a discount of 18% compared to the market price, in accordance with its valuation rules. From the first month following the IPO, the discount will be reduced by 1.5% per month.

Prior to the IPO, Quest for Growth held 508,799 shares of Kiadis, which had an approximate value of € 3.1 million. On the basis of the IPO price and the discount referred to above, the value of the Kiadis shares in Quest for Growth's portfolio increased by € 2.1 million, or € 0.18 per Quest for Growth share. This appreciation is included in the net asset value calculation as at 30 June 2015, which will be published on Thursday, 2 July.

For more information we refer to the website of Kiadis Pharma - www.kiadis.com.

About Kiadis

Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The Company believes that its innovative products have the potential to address the current risks and limitations connected with allogeneic hematopoietic stem cell transplantation (HSCT). Although currently not a viable option for many patients, HSCT is generally regarded as the most effective curative approach to blood cancers and inherited blood disorders. The Company expects that HSCT could become a first-choice treatment for blood cancers and inherited blood disorders once current risks and limitations are addressed, thereby meeting a significant unmet medical need with its products.

Press release

Leuven / 1 July 2015

Currently, ATIR™101 is being tested in an open-label Phase II trial in patients with blood cancer who have not found a matching donor and where a partially matched (haploidentical) family member is used as donor for HSCT.

Kiadis Pharma is supported by a strong group of leading international investors including LSP, Alta Partners, DFJ Esprit, Quest for Growth, MedSciences Capital and NOM. Kiadis Pharma is based in Amsterdam, The Netherlands. Further information can be found at: www.Kiadis.com

About Quest for Growth

QUEST FOR GROWTH, Privak, Undertaking for Collective Investment with fixed capital under Belgian Law. The diversified portfolio of Quest for Growth is for the most part invested in growth companies listed on European stock exchanges, in European unquoted companies and in venture capital funds. Quest for Growth focuses on innovative companies in sectors such as information- and communication technology (ICT), technology for life sciences (Health-tech) and clean technology (Cleantech). Quest for Growth has been listed on Euronext Brussels since September 23rd 1998.

www.questforgrowth.com

For further information: Capricorn Venture Partners,
asset manager of Quest for Growth
Yves Vaneerdewegh, Executive Director
+32 (0)16 28 41 00



QUEST FOR GROWTH NV

Privak, fixed capital investment company established under Belgian Law
Lei 19 - box 3, B-3000 Leuven - Phone: +32 (0)16 28 41 28 - Fax: +32 (0)16 28 41

www.questforgrowth.com
quest@questforgrowth.com